2010 compensation fell about 20 percent for top Lilly execs
Compensation for Eli Lilly and Co.’s top executives fell last year due to a change to its stock award program and as the company struggled to bring new medicines to market.
Health Care & Life Sciences
Articles
Panel OKs criminal checks on medical workers
Physicians, dentists, nurses, veterinarians, pharmacists and other medical workers would have to pay for a national criminal background check when applying for a state license under a bill pending with the Indiana Senate.
Health insurance brokers set for shakeout
Health insurance brokers, who match up employers with health insurance policies, are about to have a brighter light shone on the commissions they earn from insurers. The likely result: Commissions will fall or flatline and, eventually, fall away in favor of fee-based business models.
Struggling Lilly turns to antidepressant Cymbalta for lift
Cymbalta racked up $3.5 billion in sales last year, and some analysts say it may approach $5 billion before generic competition arrives in 2013.
Dow Agro’s quarterly sales, profit climb
Indianapolis-based Dow AgroSciences on Thursday reported record fourth-quarter revenue of $1.3 billion, up 19 percent from the prior-year period.
Lilly, Bristol-Myers halt enrollment in lung-cancer trial
Eli Lilly and Co. and Bristol-Myers Squibb Co. stopped enrolling new patients in a clinical trial of an experimental lung cancer drug over concerns about patients developing blood clots.
Potential competitor to Lilly drug shows promise in study
Sanofi-Aventis’s experimental diabetes drug lixisenatide, given to volunteer patients once a day, was at least as effective as Eli Lilly and Co. and Amylin Pharmaceuticals Inc.’s twice-daily medicine Byetta, a study found.
Marcadia may fetch up to $537 million in sale
The December sale of Carmel-based Marcadia Biotech to Roche garnered at least $287 million—and as much as $537 million—for the company’s owners and could lead the Marcadia management team to launch a firm using one of Marcadia’s experimental diabetes medicines.
Judge’s ruling raises uncertainty for health care execs
After a federal judge in Florida struck down the entire health reform law, investors shrugged. But the uncertainty for executives in health care companies increased.
Execs from WellPoint, peers meet to hone health-law lobby
Top executives from WellPoint Inc. and UnitedHealth Group Inc. are meeting almost monthly with their counterparts from Aetna Inc., Cigna Corp. and Humana Inc. in an informal lobbying alliance aimed at blunting parts of the health-care law, say sources with knowledge of the sessions.
Loopholes give smoking ban bill a better chance
A proposed statewide smoking ban now has so many exemptions that health advocates say it nearly loses its meaning.
Endocyte plans to raise about $78 million in IPO
The West Lafayette company does not yet market a product and has not yet reported a profit.
King Systems’ two top execs exit company
An executive at the Noblesville firm’s parent company said the departures of CEO Don Dumoulin and Chief Financial Officer Yun Kim were the result of a “mutual agreement.” A search is under way for replacements to lead one of the area’s largest medical device manufacturers.
Marketing firm VMS plans growth, new jobs
Event-planning powerhouse VMS Inc. plans to invest more than $1.5 million to expand its Indianapolis life sciences marketing operation and create as many as 102 jobs over the next four years, state officials said Friday morning.
Indiana Health Information Exchange hires new CEO
Harold Apple takes over for J. Marc Overhage, who will remain with the organization as its chief strategic officer and national policy adviser. IHIE is one of four operational exchanges in Indiana that allows for the sharing of medical records electronically.
Lilly’s fourth-quarter profit surges, topping analysts’ predictions
The Indianapolis-based drugmaker earned $1.2 billion in the quarter, compared with $915 million in the same period a year ago. Profit per share beat Wall Street forecasts by a penny.
WellPoint profit better than analyst estimates
Excluding special charges, WellPoint’s profit fell 2 percent to $524.7 million in the fourth quarter from $536 million in the fourth quarter of 2009. But earnings per share improved thanks to stock buybacks.
Lilly product gets boost; Wall Street yawns
Eli Lilly and Co. probably will get approval for its newly acquired imaging agent used to diagnose Alzheimer’s disease, but so far analysts are unimpressed.
Q&A
Chris Sears is a health care and employee-benefits attorney at Ice Miller LLP in Indianapolis. He spoke about how employers are sizing up health insurance reforms that hit in 2014, which would set up government-subsidized insurance as a new option for workers but also would penalize most employers if they stop sponsoring employee health benefits.
Life sciences to drive Purdue’s next decade of building
Over the past 10 years, Purdue University has built Discovery Park into a thriving research and business incubation center, launching more than 30 companies and hosting dozens more. Now Purdue will spend more than $164 million to construct a Life and Health Sciences Quadrangle next to Discovery Park.